Will Trump's Drug Order Put The Brakes On China's Overseas Pharma Drive?
The U.S. president has promised to reduce prescription drug prices by 30% to 80% for Americans, insisting they are entitled to prices paid in other developed countries. Pharma company stocks tumbled after Donald Trump announced a plan to reduce U.S. drug prices, but regained some ground on belief ...
Coherus BioSciences ( CHRS ) Reports Q1 Loss, Lags Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -12.90% and 85.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
- Strategic transformation to innovative oncology completed in ...
Coherus to Participate in Upcoming Investor Conferences - Coherus BioSciences ( NASDAQ:CHRS )
REDWOOD CITY, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( ( "Coherus, NASDAQ:CHRS ) today announced that the company will be webcasting its participation in the upcoming conferences: Citizens Life Science Conference in New York, NY on Thursday, May 8, 2025 at ...
Coherus to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( "Coherus," NASDAQ: CHRS ) today announced that the company will be webcasting its participation in the upcoming conferences: ...
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 - Coherus BioSciences ( NASDAQ:CHRS )
- CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab - - Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab -
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
- CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with ...
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
- Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture -
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
- Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture ...
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, March 28, 2025 ( GLOBE NEWSWIRE ) -- Shanghai Junshi Biosciences Co., Ltd ( "Junshi Biosciences," HKEX: 1877. SSE: 688180 ) , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial ...
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
- Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures -- UDENYCA® net revenue increased 62% year-over-year -- LOQTORZI® net revenue increased ...
Arcturus Therapeutics ( ARCT ) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -226.47% and 60.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
REDWOOD CITY, Calif., March 03, 2025 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( "Coherus," NASDAQ: CHRS ) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m.
Fortrea Holdings Inc. ( FTRE ) Q4 Earnings and Revenues Miss Estimates
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -50% and 0.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference - Coherus BioSciences ( NASDAQ:CHRS )
REDWOOD CITY, Calif., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( ( "Coherus, NASDAQ:CHRS ) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m., ...
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
REDWOOD CITY, Calif., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( "Coherus," NASDAQ: CHRS ) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m., ...
VistaGen Therapeutics, Inc. ( VTGN ) Reports Q3 Loss, Misses Revenue Estimates
VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 8% and 35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down
Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.
Codexis Appoints Christos Richards to Board of Directors - Codexis ( NASDAQ:CDXS )
REDWOOD CITY, Calif., Jan. 16, 2025 ( GLOBE NEWSWIRE ) -- Codexis, Inc. CDXS, a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company's Board of Directors.
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases
CAMBRIDGE, Mass., Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Neutrolis Inc., a clinical stage biotech company focused on targeting Neutrophil Extracellular Traps ( NETs ) for the treatment of autoimmune and inflammatory diseases, today announced the expansion of its senior leadership team to support ...
Why Is Coherus BioSciences Stock Trading Higher On Tuesday? - Sandoz Group ( OTC:SDZNY ) , Coherus BioSciences ( NASDAQ:CHRS )
On Tuesday, Coherus BioSciences, Inc. CHRS entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of the Udenyca ( pegfilgrastim-cbqv ) franchise for up to $558.4 million.
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma
Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma.
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( "Coherus," NASDAQ: CHRS ) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel ...
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference - Coherus BioSciences ( NASDAQ:CHRS )
REDWOOD CITY, Calif., Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( ( "Coherus, NASDAQ:CHRS ) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel ... ET.
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Partnerships will employ Vaccinex's ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
Coherus BioSciences ( CHRS ) Reports Q3 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 90% and 24.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare ( ACHC ) Beats Q3 Earnings Estimates
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 1.11% and 0.40%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 - Coherus BioSciences ( NASDAQ:CHRS )
REDWOOD CITY, Calif., Oct. 30, 2024 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( ( "Coherus, NASDAQ:CHRS ) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m.
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company - Codexis ( NASDAQ:CDXS )
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, Calif., Oct. 02, 2024 ( GLOBE NEWSWIRE ) -- Codexis, Inc.
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
Company raises $31 million through ATM, bringing cash runway into ...
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
SHANGHAI, Aug. 30, 2024 ( GLOBE NEWSWIRE ) -- Shanghai Junshi Biosciences Co., Ltd ( "Junshi Biosciences," HKEX: 1877. SSE: 688180 ) , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2024 ...
Coherus BioSciences ( CHRS ) Reports Q2 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 33.33% and 13.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer - PR Newswire
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer PR ...
StockNews.com Upgrades Coherus BioSciences ( NASDAQ:CHRS ) to "Buy"
Coherus BioSciences ( NASDAQ:CHRS - Get Free Report ) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on Thursday. CHRS has been the topic of several other research reports.
Coherus BioSciences ( NASDAQ:CHRS ) Upgraded to "Buy" at StockNews.com
StockNews.com upgraded shares of Coherus BioSciences ( NASDAQ:CHRS - Free Report ) from a hold rating to a buy rating in a report published on Thursday. Several other research analysts have also weighed in on the company. Robert W.
Apotex Further Expands Oncology Franchise Through the Acquisition of Canadian Rights to Toripalimab
Toripalimab becomes Apotex's first novel brand biologic medicine
Coherus BioSciences Announces Divestiture of YUSIMRY ( adalimumab-aqvh ) in a $40 Million Upfront All Cash Transaction
- Transaction aligns with Coherus' strategic focus on oncology - - Transaction aligns with Coherus' strategic focus on oncology ...
Nurix Therapeutics Appoints Paula G. O'Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies ...
Nurix Therapeutics Appoints Paula G. O'Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer - Nurix Therapeutics ( NASDAQ:NRIX )
SAN FRANCISCO, May 28, 2024 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics, Inc. NRIX, a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointments of Paula G.
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 ( CCR8 ) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology ( ASCO ) Annual Meeting - Coherus BioSciences ( NASDAQ:CHRS )
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities ( DLTs ) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells ( Tregs ) was observed and depletion was maintained over the dosing interval, establishing ...
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 ( CCR8 ) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology ( ASCO ) Annual Meeting
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities ( DLTs ) in heavily pretreated patients with solid tumors ...
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA - Coherus BioSciences ( NASDAQ:CHRS )
REDWOOD CITY, Calif., May 23, 2024 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( ( Coherus, NASDAQ:CHRS ) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 ...
Inovio Pharmaceuticals ( INO ) Q1 2024 Earnings Call Transcript
INO earnings call for the period ending March 31, 2024.
Coherus BioSciences ( CHRS ) Reports Q1 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -540% and 24.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan - Coherus BioSciences ( NASDAQ:CHRS )
- New $38.7 million term loan with a May 2029 maturity - - $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® -
Editas Medicine ( EDIT ) Reports Q1 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -20.63% and 90.26%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Sandoz reports first quarter 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology ( ASCO ) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( Coherus, Nasdaq: CHRS ) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 ...
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting - Coherus BioSciences ( NASDAQ:CHRS )
- In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion - - Mechanism may enhance antitumor responses with immunotherapy - - First novel immuno-oncology ...
Why Coherus Biosciences Stock Tumbled on Thursday
The company fell well short of expectations for its fourth quarter.
